UY35526A - Derivados de espiroindolina y composiciones farma céuticas de los mismos - Google Patents

Derivados de espiroindolina y composiciones farma céuticas de los mismos

Info

Publication number
UY35526A
UY35526A UY0001035526A UY35526A UY35526A UY 35526 A UY35526 A UY 35526A UY 0001035526 A UY0001035526 A UY 0001035526A UY 35526 A UY35526 A UY 35526A UY 35526 A UY35526 A UY 35526A
Authority
UY
Uruguay
Prior art keywords
spiroindoline
derivatives
compositions
céuticas
sisos
Prior art date
Application number
UY0001035526A
Other languages
English (en)
Inventor
Ring Sven
Dr Olaf Panknin
Dr Stefan Bäurle
Dr Reinhard Nubbemeyer
Dr Gernot Langer
Dr Katrin Nowak-Reppel
Dr Andrea Wagenfeld
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35526A publication Critical patent/UY35526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Abstract

Derivados de espiroindolina, procesos para su preparación y composiciones farmacéuticas con los mismos, su uso para el tratamiento de enfermedades y su uso en la elaboración de medicamentos para el tratamiento de enfermedades, en especial enfermeda des relacionadas con las hormonas sexuales, tanto en hombres como en mujeres. La presente solicitud se relaciona en particular con derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina (GnRH).
UY0001035526A 2013-04-09 2014-04-09 Derivados de espiroindolina y composiciones farma céuticas de los mismos UY35526A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09

Publications (1)

Publication Number Publication Date
UY35526A true UY35526A (es) 2014-11-28

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035526A UY35526A (es) 2013-04-09 2014-04-09 Derivados de espiroindolina y composiciones farma céuticas de los mismos

Country Status (28)

Country Link
US (1) US20160052936A1 (es)
EP (1) EP2984092A1 (es)
JP (1) JP2016519104A (es)
KR (1) KR20150139917A (es)
CN (1) CN105308053A (es)
AP (1) AP2015008822A0 (es)
AR (1) AR095785A1 (es)
AU (1) AU2014253232A1 (es)
BR (1) BR112015025700A2 (es)
CA (1) CA2908869A1 (es)
CL (1) CL2015003013A1 (es)
CR (1) CR20150530A (es)
CU (1) CU20150141A7 (es)
DO (1) DOP2015000259A (es)
EA (1) EA201501000A1 (es)
HK (1) HK1216101A1 (es)
IL (1) IL241067A0 (es)
MA (1) MA38463B1 (es)
MX (1) MX2015014267A (es)
NI (1) NI201500149A (es)
PE (1) PE20160007A1 (es)
PH (1) PH12015502318A1 (es)
SG (1) SG11201506962TA (es)
TN (1) TN2015000453A1 (es)
TW (1) TW201518304A (es)
UY (1) UY35526A (es)
WO (1) WO2014166958A1 (es)
ZA (1) ZA201508209B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280742B2 (en) 2017-06-05 2023-12-21 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
SG11201403749VA (en) * 2012-01-16 2014-07-30 Bayer Ip Gmbh Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Also Published As

Publication number Publication date
BR112015025700A2 (pt) 2017-07-18
DOP2015000259A (es) 2015-11-15
EA201501000A1 (ru) 2016-04-29
MX2015014267A (es) 2016-03-01
HK1216101A1 (zh) 2016-10-14
KR20150139917A (ko) 2015-12-14
ZA201508209B (en) 2018-05-30
TN2015000453A1 (en) 2017-04-06
NI201500149A (es) 2015-11-30
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
CR20150530A (es) 2016-01-29
WO2014166958A1 (en) 2014-10-16
US20160052936A1 (en) 2016-02-25
MA38463A1 (fr) 2018-05-31
CL2015003013A1 (es) 2016-04-08
CU20150141A7 (es) 2016-03-31
CN105308053A (zh) 2016-02-03
IL241067A0 (en) 2015-11-30
PE20160007A1 (es) 2016-02-14
JP2016519104A (ja) 2016-06-30
AP2015008822A0 (en) 2015-10-31
EP2984092A1 (en) 2016-02-17
AR095785A1 (es) 2015-11-11
CA2908869A1 (en) 2014-10-16
MA38463B1 (fr) 2018-11-30
SG11201506962TA (en) 2015-10-29
AU2014253232A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206